News in the treatment of axial spondyloarthritis

Czech version

Authors: Martin Žurek; Pavel Horák
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická FN Olomouc
Published in: Vnitř Lék 2022; 68(5): 279-284
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.060

Overview

Axial spondyloarthritis is a rheumatic disease characterized by inflammation and bone formation causing impaired function of the spine and affected joints. Basic research has highlighted the key role of dysregulation of tumor necrosis factor α, interleukin- 23 and interleukin-17 cytokine production in the etiology of axial spondyloarthritis. Tumor necrosis factor α and interleukin-17 inhibitors have been shown to be effective in clinical trials and are currently approved biological disease-modifying drugs for all disease subgroups. The presumed efficacy of IL-23 blockade has not been confirmed in two clinical trials with anti-IL-23 monoclonal antibodies. Janus kinase inhibitors appear to be a new treatment option.

Keywords:

axial spondyloarthritis – tumor necrosis factor α inhibitors – interleukin-17 inhibitors – interleukin-23 inhibitors – Janus kinase inhibitors

Sources

1. Rudwaleit M, van der Heijde D, Landewe’ R et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.

2. Lories RJ, Haroon N. Evolving concepts of new bone formation in axial spondyloarthritis: insights from animal models and human studies. Best Pract Res Clin Rheumatol. 2017;31(6):877-886.

3. Regnaux JP, Davergne T, Palazzo C et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev. 2019;10:CD011321.

4. Kroon FP, van der Burg LR, Ramiro S et al. Non‑steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‑radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;(7):CD010952.

5. van der Heijde D, Ramiro S, Landewé R et al. 2016 update of the ASASEULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):78-91.

6. Maxwell LJ, Zochling J, Boonen A et al. TNF‑alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.

7. Karmacharya P, Duarte‑Garcia A, Dubreuil M et al. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta‑analysis. Arthritis Rheumatol. 2020;72(5):733-749.

8. Lian F, Zhou J, Wang Y et al. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018;36(5):884-890.

9. Maxwell LJ, Zochling J, Boonen A et al. TNF‑alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.

10. Baraliakos X, Braun J, Deodhar A et al. Long‑term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005.

11. Deodhar A, van der Heijde D, Gensler LS et al. Ixekizumab for patients with non‑radiographic axial spondyloarthritis (COAST‑X): a randomised, placebocontrolled trial. Lancet. 2020;395(10217):53-64.

12. Wang P, Zhang S, Hu B et al. Efficacy and safety of interleukin-17 A inhibitors in patients with ankylosing spondylitis: a systematic review and meta‑analysis of randomized controlled trials. Clin Rheumatol. 2021;40(8):3053-3065.

13. Deodhar A, Gensler LS, Sieper J et al. Three multicenter, randomized, double‑blind, placebo‑ controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-270.

14. Baeten D, Østergaard M, Wei JC‑ C et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double‑blind, placebo‑ controlled, proof‑ofconcept, dose‑finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295-302.

15. van Tok MN, Na S, Lao CR et al. The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol. 2018;9:1550.

16. Gracey E, Qaiyum Z, Almaghlouth I et al. IL-7 primes IL- 17 in mucosal‑associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124-32.

17. Noack M, Ndongo‑Thiam N, Miossec P. Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Res Ther. 2016;18:14.

18. van der Heijde D, Deodhar A, Wei JC et al. Tofacitinib in patients with ankylosing spondylitis a phase II, 16 week randomised, placebo controlled study. Ann Rheum Dis. 2017;76:1340-1347.

19. Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology. 2018;57:1390-1399.

20. Deodhar A, Sliwinska‑Stanczyk P, Xu H et al. Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double‑blind, Placebo‑ controlled Study. Abstract. ACR 2020.

21. van der Heijde D, Song I‑H, Pangan AL et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT‑AXIS 1): a multicentre, randomised, double‑blind, placebo‑ controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108-2117.

22. van der Heijde D, Baraliakos X, Gensler LS et al. Efficacyand safety of filgotinib, a selective Janus kinase 1inhibitor, in patients with active ankylosing spondylitis(TORTUGA): results from a randomised, placebocontrolled, phase 2 trial. Lancet. 2018;392(10162):2378-2387.

23. Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta‑analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-76.